目的 探讨奥马珠单抗联合复方甘草酸苷治疗抗组胺药低反应慢性荨麻疹的疗效及安全性。 方法 选取2022年2月至2024年2月医院收治的经H1抗组胺药治疗后症状仍未消退的92例慢性荨麻疹患者为研究对象，以随机数字表法分为观察组46例和对照组46例。对照组皮下注射奥马珠单抗治疗。观察组在对照组基础上，口服复方甘草酸苷片治疗。治疗24周后，比较两组的疗效、不良反应、7 d荨麻疹活动度评分（Urticaria Activity Score over 7 days，UAS7）、皮肤病生活质量指数（Dermatology Life Quality Index， DLQI）、免疫球蛋白（immunoglobulin， Ig）E、超敏C反应蛋白（high-sensitivity C-reactive protein， hs-CRP），记录复发率。 结果 治疗后，两组UAS7、DLQI、IgE、hs-CRP较治疗前均降低，观察组低于对照组（P < 0.05）。治疗后，观察组的总有效率高于对照组（P < 0.05），复发率低于对照组（P < 0.05）。两组药物不良反应发生率比较，差异无统计学意义（P > 0.05）。 结论 奥马珠单抗联合复方甘草酸苷治疗抗组胺药低反应慢性荨麻疹患者，有助于降低IgE表达，提高治疗有效率，降低复发率，且未增加药物不良反应。

Objective To investigate the effectiveness and safety of combining Omalizumab with compound glycyrrhetinic acid glycoside in the management of chronic urticaria that exhibits poor response to antihistamine therapy. Methods 92 patients with chronic urticaria who were treated with H1 antihistamines and still had symptoms from February 2022 to February 2024 in the hospital were selected as the study subjects. The study participants were randomly assigned to either the observation group， consisting of 46 cases， or the control group， also comprising 46 cases， using a random number table method. The control group received subcutaneous injection of omalizumab for treatment. The observation group was treated with oral compound glycyrrhizin tablets on the basis of the control group. After 24 weeks of treatment， compare the efficacy， adverse reactions， Urticaria Activity Score over 7 days （UAS7）， Dermatology Life Quality Index （DLQI）， Immunoglobulin （Ig） E， and High Sensitivity C-reactive protein （hs CRP） between the two groups， and record the recurrence rate. Results After treatment， the UAS7， DLQI， IgE and hs-CRP of both groups of patients decreased compared to before treatment， and the observation group demonstrated lower results compared to the control group （P < 0.05）. After treatment， the overall effectiveness rate in the observation group exceeded that of the control group（P < 0.05）， and the recurrence rate was lower than that of the control group （P < 0.05）. There was no statistically significant difference in the incidence of adverse reactions between the two groups of drugs （P > 0.05）. Conclusion The combination therapy of omalizumab and compound glycyrrhetinic acid glycoside in the treatment of chronic urticaria patients with low response to antihistamines helps reduce IgE expression， improve treatment effectiveness， lower recurrence rates， and does not increase adverse drug reactions.